期刊文献+

二次检索

题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息
共找到2篇文章
< 1 >
每页显示 20 50 100
Increase of CD4^+CD25^+ T cells in Smad3^(-/-) mice 被引量:3
1
作者 zi-bing wang Yu-Fang Cui +7 位作者 Yu-Qing Liu Wei Jin Han Xu Zhu-Jun Jiang Ya-Xin Lu Ying Zhang Xiao-Lan Liu Bo Dong 《World Journal of Gastroenterology》 SCIE CAS CSCD 2006年第15期2455-2458,共4页
AIM: To investigate the changes of lymphocyte subpopulations, especially CD4^+CD25^ T regulatory cells in Smad3^-/- mice. METHODS: Hematological changes and changes of lymphocyte subpopulations were detected in Sm... AIM: To investigate the changes of lymphocyte subpopulations, especially CD4^+CD25^ T regulatory cells in Smad3^-/- mice. METHODS: Hematological changes and changes of lymphocyte subpopulations were detected in Smad3"/- mice using cell counter and flow cytometry, respectively, and compared to their littermate controls. RESULTS: The numbers of neutrophils and lymphocytes in peripheral blood were significantly increased in Smad3^-/- mice compared to littermate controls. CD19^+ expressing cells in blood and spleen, and CD8^+ T cells in thymus were all markedly decreased in Smad3^-/- mice. More important, Smad3^-/- mice had an increased population of CD4^+CD25^+ T cells in peripheral lymphoid tissues, including thymus, spleen, and lymph nodes. CONCLUSION: These observations suggest that the changes of lymphocyte subpopulations might play a role in susceptibility to inflammation of Smad3^-/- mice. 展开更多
关键词 CD4^+CD25^+ T cells Lymphocyte subpopulation SMAD3 TGF-β signaling
下载PDF
Gefitinib(an EGFR tyrosine kinase inhibitor)plus anlotinib(an multikinase inhibitor)for untreated,EGFR-mutated,advanced non-small cell lung cancer(FL-ALTER):a multicenter phase III trial
2
作者 Hua-Qiang Zhou Ya-Xiong Zhang +22 位作者 Gang Chen Qi-Tao Yu Hua Zhang Guo-Wu Wu Di Wu Ying-Cheng Lin Jun-Fei Zhu Jian-Hua Chen Xiao-Hua Hu Bin Lan Ze-Qiang Zhou Hai-Feng Lin zi-bing wang Xiao-Lin Lei Suo-Ming Pan Li-Ming Chen Jian Zhang Tian-Dong Kong Ji-Cheng Yao Xin Zheng Feng Li Li Zhang Wen-Feng Fang 《Signal Transduction and Targeted Therapy》 SCIE CSCD 2024年第9期4091-4102,共12页
Dual inhibition of vascular endothelial growth factor and epidermal growth factor receptor(EGFR)signaling pathways offers the prospect of improving the effectiveness of EFGR-targeted therapy.In this phase 3 study(Clin... Dual inhibition of vascular endothelial growth factor and epidermal growth factor receptor(EGFR)signaling pathways offers the prospect of improving the effectiveness of EFGR-targeted therapy.In this phase 3 study(ClinicalTrial.gov:NCT04028778),315 patients with treatment-naïve,EGFR-mutated,advanced non-small cell lung cancer(NSCLC)were randomized(1:1)to receive anlotinib or placebo plus gefitinib once daily on days 1–14 per a 3-week cycle.At the prespecified final analysis of progression-free survival(PFS),a significant improvement in PFS was observed for the anlotinib arm over the placebo arm(hazards ratio[HR]=0.64,95%CI,0.48–0.80,P=0.003).Particularly,patients with brain metastasis and those harboring EGFR amplification or high tumor mutation load gained significant more benefits in PFS from gefitinib plus anlotinib.The incidence of grade 3 or higher treatment-emergent adverse events was 49.7%of the patients receiving gefitinib plus anlotinib versus 31.0%of the patients receiving gefitinib plus placebo.Anlotinib plus gefitinib significantly improves PFS in patients with treatment-naïve,EGFR-mutated,advanced NSCLC,with a manageable safety profile. 展开更多
关键词 cancer lung treatment
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部